Scarica l'app Stockscreener
341.51
6.91%
-25.34
Dopo l'orario di chiusura:
340.00
-1.51
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$366.85
Aprire:
$364.66
Volume 24 ore:
430.85K
Relative Volume:
1.07
Capitalizzazione di mercato:
$10.07B
Reddito:
$417.30M
Utile/perdita netta:
$225.03M
Rapporto P/E:
45.65
EPS:
7.4815
Flusso di cassa netto:
$237.38M
1 W Prestazione:
+1.89%
1M Prestazione:
-8.11%
6M Prestazione:
+22.30%
1 anno Prestazione:
+121.95%
Intervallo 1D:
$340.55
$367.30
Intervallo di 1 settimana:
$334.38
$369.00
Portata 52W:
$130.50
$382.54
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
341.51 | 10.37B | 417.30M | 225.03M | 237.38M | 7.4815 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-05 | Iniziato | Jefferies | Buy |
| 2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-18 | Iniziato | BofA Securities | Buy |
| 2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-06-04 | Iniziato | Evercore ISI | Outperform |
| 2019-09-24 | Iniziato | Goldman | Neutral |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-30 | Iniziato | Guggenheim | Buy |
| 2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
Krystal Biotech Inc (KRYS) Institutional Confidence - TradingKey
Krystal Biotech Inc (KRYS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Krystal Biotech Inc (KRYS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: Biotechnology Pioneer with 12.40% Potential Upside - DirectorsTalk Interviews
KRYS|Krystal Biotech Inc|Price:352.060|Chg%:+16.870 - TradingKey
TradingKey - TradingKey
Krystal Biotech Inc (KRYS) Income Statement - TradingKey
Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech, Inc. Revenue Breakdown – NASDAQ:KRYS - TradingView
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Price, News, Quote & History - Yahoo! Finance Canada
KRYS|Krystal Biotech Inc|Price:335.190|Chg%:+7.690 - TradingKey
Krystal Biotech, Inc. (KRYS) stock price, news, quote and history - Yahoo Finance UK
Krystal Biotech Inc (KRYS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Krystal Biotech, Inc.(NasdaqGS: KRYS) added to S&P 400Biotechnology - marketscreener.com
Krystal Biotech, Inc.(NasdaqGS: KRYS) added to S&P 400 Health Care - marketscreener.com
Krystal Biotech, Inc.(NasdaqGS: KRYS) dropped from S&P 600 Health Care - marketscreener.com
Krystal Biotech, Inc.(NasdaqGS: KRYS) dropped from S&P 600 - marketscreener.com
Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 - The Manila Times
Krystal Biotech sets Aug. 3 webcast before U.S. markets open - Stock Titan
Krystal Biotech updates financial calendar with quarterly results release, conference call - Bitget
Krystal Biotech Reveals Single-Patient Data from Discontinued KB801 Trial in Patent Filing - Kalkine Media
Krystal BiotechFiles Response With Uspto On Kb801 Patent ApplicationSEC Filing - TradingView
Why Tutor Perini Stock Trounced the Market on Tuesday - The Motley Fool
Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech (KRYS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech (KRYS) Joins S&P MidCap 400 Amid Index Changes - GuruFocus
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 - Finansavisen
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring a $10 Billion Valuation and Strategic Growth in Genetic Medicine - DirectorsTalk Interviews
(KRYS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
KRYS Jumps As Wall Street Hikes Price Targets On Vyjuvek Momentum - StocksToTrade
KRYS Jumps As Analysts Race To Lift Price Targets - StocksToTrade
KRYS Jumps As Wall Street Lifts Bullish Price Targets - StocksToTrade
Krystal Biotech Rises as Investors Lean on Commercial Momentum and Pipeline Catalysts - Quiver Quantitative
Krystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setup - ChartMill
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $396 - Moomoo
ETFs Investing in Krystal Biotech, Inc. Stocks - TradingView
Krystal Biotech, Inc. Stock 12‑Month Price Target Raised to $369.44, Implies 1% Upside - TradingView
Jefferies Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $474 - Moomoo
BofA raises Krystal Biotech stock price target on Vyjuvek growth By Investing.com - Investing.com Nigeria
BofA raises Krystal Biotech stock price target on Vyjuvek growth - Investing.com
Krystal Biotech Stock And 2 Biotech Names With Pipeline Catalysts - Sahm
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
Is the options market predicting a spike in Krystal Biotech stock? - MSN
Here's why Krystal Biotech, Inc. (KRYS) is a strong momentum stock - MSN
Analysts see more upside for Abivax, Krystal Biotech, Marvell - MSN
3 Soaring Stocks That May Have More Upside Ahead - The Globe and Mail
Krystal Biotech focuses on gene-based dermatology treatments as investors watch long-term growth - ad-hoc-news.de
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Krystal Biotech Inc Azioni (KRYS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Thomas John Charles | EVP, General Counsel |
Jun 25 '26 |
Sale |
347.27 |
1,000 |
347,270 |
0 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):